The objective of this study was to investigate whether the dosing regimen of tiotropium (once-versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-hour bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.